Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective
• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and comp...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Karawajczyk, Anna [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2015 |
|---|
| Umfang: |
7 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Triazolopyridazine LRRK2 kinase inhibitors - 2013, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:20 ; year:2015 ; number:11 ; pages:1310-1316 ; extent:7 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.drudis.2015.09.009 |
|---|
| Katalog-ID: |
ELV023891211 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV023891211 | ||
| 003 | DE-627 | ||
| 005 | 20230623171943.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.drudis.2015.09.009 |2 doi | |
| 028 | 5 | 2 | |a GBVA2015019000019.pica |
| 035 | |a (DE-627)ELV023891211 | ||
| 035 | |a (ELSEVIER)S1359-6446(15)00349-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 540 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 630 |q VZ |
| 084 | |a 22 |2 ssgn | ||
| 084 | |a 46.00 |2 bkl | ||
| 100 | 1 | |a Karawajczyk, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| 264 | 1 | |c 2015 | |
| 300 | |a 7 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. | ||
| 700 | 1 | |a Giordanetto, Fabrizio |4 oth | |
| 700 | 1 | |a Benningshof, Jorg |4 oth | |
| 700 | 1 | |a Hamza, Daniel |4 oth | |
| 700 | 1 | |a Kalliokoski, Tuomo |4 oth | |
| 700 | 1 | |a Pouwer, Kees |4 oth | |
| 700 | 1 | |a Morgentin, Remy |4 oth | |
| 700 | 1 | |a Nelson, Adam |4 oth | |
| 700 | 1 | |a Müller, Gerhard |4 oth | |
| 700 | 1 | |a Piechot, Alexander |4 oth | |
| 700 | 1 | |a Tzalis, Dimitrios |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |t Triazolopyridazine LRRK2 kinase inhibitors |d 2013 |g Amsterdam [u.a.] |w (DE-627)ELV011759550 |
| 773 | 1 | 8 | |g volume:20 |g year:2015 |g number:11 |g pages:1310-1316 |g extent:7 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.drudis.2015.09.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 46.00 |j Tiermedizin: Allgemeines |q VZ |
| 951 | |a AR | ||
| 952 | |d 20 |j 2015 |e 11 |h 1310-1316 |g 7 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
a k ak |
|---|---|
| matchkey_str |
karawajczykannagiordanettofabriziobennin:2015----:xasooceiasaeoclaoaieedeeainndudsoeyhe |
| hierarchy_sort_str |
2015 |
| bklnumber |
46.00 |
| publishDate |
2015 |
| allfields |
10.1016/j.drudis.2015.09.009 doi GBVA2015019000019.pica (DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Karawajczyk, Anna verfasserin aut Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. Giordanetto, Fabrizio oth Benningshof, Jorg oth Hamza, Daniel oth Kalliokoski, Tuomo oth Pouwer, Kees oth Morgentin, Remy oth Nelson, Adam oth Müller, Gerhard oth Piechot, Alexander oth Tzalis, Dimitrios oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:20 year:2015 number:11 pages:1310-1316 extent:7 https://doi.org/10.1016/j.drudis.2015.09.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 20 2015 11 1310-1316 7 045F 610 |
| spelling |
10.1016/j.drudis.2015.09.009 doi GBVA2015019000019.pica (DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Karawajczyk, Anna verfasserin aut Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. Giordanetto, Fabrizio oth Benningshof, Jorg oth Hamza, Daniel oth Kalliokoski, Tuomo oth Pouwer, Kees oth Morgentin, Remy oth Nelson, Adam oth Müller, Gerhard oth Piechot, Alexander oth Tzalis, Dimitrios oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:20 year:2015 number:11 pages:1310-1316 extent:7 https://doi.org/10.1016/j.drudis.2015.09.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 20 2015 11 1310-1316 7 045F 610 |
| allfields_unstemmed |
10.1016/j.drudis.2015.09.009 doi GBVA2015019000019.pica (DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Karawajczyk, Anna verfasserin aut Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. Giordanetto, Fabrizio oth Benningshof, Jorg oth Hamza, Daniel oth Kalliokoski, Tuomo oth Pouwer, Kees oth Morgentin, Remy oth Nelson, Adam oth Müller, Gerhard oth Piechot, Alexander oth Tzalis, Dimitrios oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:20 year:2015 number:11 pages:1310-1316 extent:7 https://doi.org/10.1016/j.drudis.2015.09.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 20 2015 11 1310-1316 7 045F 610 |
| allfieldsGer |
10.1016/j.drudis.2015.09.009 doi GBVA2015019000019.pica (DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Karawajczyk, Anna verfasserin aut Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. Giordanetto, Fabrizio oth Benningshof, Jorg oth Hamza, Daniel oth Kalliokoski, Tuomo oth Pouwer, Kees oth Morgentin, Remy oth Nelson, Adam oth Müller, Gerhard oth Piechot, Alexander oth Tzalis, Dimitrios oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:20 year:2015 number:11 pages:1310-1316 extent:7 https://doi.org/10.1016/j.drudis.2015.09.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 20 2015 11 1310-1316 7 045F 610 |
| allfieldsSound |
10.1016/j.drudis.2015.09.009 doi GBVA2015019000019.pica (DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Karawajczyk, Anna verfasserin aut Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective 2015 7 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier • High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. Giordanetto, Fabrizio oth Benningshof, Jorg oth Hamza, Daniel oth Kalliokoski, Tuomo oth Pouwer, Kees oth Morgentin, Remy oth Nelson, Adam oth Müller, Gerhard oth Piechot, Alexander oth Tzalis, Dimitrios oth Enthalten in Elsevier Science Triazolopyridazine LRRK2 kinase inhibitors 2013 Amsterdam [u.a.] (DE-627)ELV011759550 volume:20 year:2015 number:11 pages:1310-1316 extent:7 https://doi.org/10.1016/j.drudis.2015.09.009 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 46.00 Tiermedizin: Allgemeines VZ AR 20 2015 11 1310-1316 7 045F 610 |
| language |
English |
| source |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:20 year:2015 number:11 pages:1310-1316 extent:7 |
| sourceStr |
Enthalten in Triazolopyridazine LRRK2 kinase inhibitors Amsterdam [u.a.] volume:20 year:2015 number:11 pages:1310-1316 extent:7 |
| format_phy_str_mv |
Article |
| bklname |
Tiermedizin: Allgemeines |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| authorswithroles_txt_mv |
Karawajczyk, Anna @@aut@@ Giordanetto, Fabrizio @@oth@@ Benningshof, Jorg @@oth@@ Hamza, Daniel @@oth@@ Kalliokoski, Tuomo @@oth@@ Pouwer, Kees @@oth@@ Morgentin, Remy @@oth@@ Nelson, Adam @@oth@@ Müller, Gerhard @@oth@@ Piechot, Alexander @@oth@@ Tzalis, Dimitrios @@oth@@ |
| publishDateDaySort_date |
2015-01-01T00:00:00Z |
| hierarchy_top_id |
ELV011759550 |
| dewey-sort |
3610 |
| id |
ELV023891211 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023891211</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623171943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2015.09.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015019000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023891211</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(15)00349-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Karawajczyk, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giordanetto, Fabrizio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benningshof, Jorg</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamza, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalliokoski, Tuomo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pouwer, Kees</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morgentin, Remy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nelson, Adam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Müller, Gerhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piechot, Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tzalis, Dimitrios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1310-1316</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2015.09.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2015</subfield><subfield code="e">11</subfield><subfield code="h">1310-1316</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Karawajczyk, Anna |
| spellingShingle |
Karawajczyk, Anna ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| authorStr |
Karawajczyk, Anna |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV011759550 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 540 - Chemistry & allied sciences 630 - Agriculture & related technologies |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| topic |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_unstemmed |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| topic_browse |
ddc 610 ddc 540 ddc 630 ssgn 22 bkl 46.00 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
f g fg j b jb d h dh t k tk k p kp r m rm a n an g m gm a p ap d t dt |
| hierarchy_parent_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| hierarchy_parent_id |
ELV011759550 |
| dewey-tens |
610 - Medicine & health 540 - Chemistry 630 - Agriculture |
| hierarchy_top_title |
Triazolopyridazine LRRK2 kinase inhibitors |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV011759550 |
| title |
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| ctrlnum |
(DE-627)ELV023891211 (ELSEVIER)S1359-6446(15)00349-9 |
| title_full |
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| author_sort |
Karawajczyk, Anna |
| journal |
Triazolopyridazine LRRK2 kinase inhibitors |
| journalStr |
Triazolopyridazine LRRK2 kinase inhibitors |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2015 |
| contenttype_str_mv |
zzz |
| container_start_page |
1310 |
| author_browse |
Karawajczyk, Anna |
| container_volume |
20 |
| physical |
7 |
| class |
610 610 DE-600 540 VZ 610 VZ 630 VZ 22 ssgn 46.00 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Karawajczyk, Anna |
| doi_str_mv |
10.1016/j.drudis.2015.09.009 |
| dewey-full |
610 540 630 |
| title_sort |
expansion of chemical space for collaborative lead generation and drug discovery: the european lead factory perspective |
| title_auth |
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| abstract |
• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. |
| abstractGer |
• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. |
| abstract_unstemmed |
• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
11 |
| title_short |
Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective |
| url |
https://doi.org/10.1016/j.drudis.2015.09.009 |
| remote_bool |
true |
| author2 |
Giordanetto, Fabrizio Benningshof, Jorg Hamza, Daniel Kalliokoski, Tuomo Pouwer, Kees Morgentin, Remy Nelson, Adam Müller, Gerhard Piechot, Alexander Tzalis, Dimitrios |
| author2Str |
Giordanetto, Fabrizio Benningshof, Jorg Hamza, Daniel Kalliokoski, Tuomo Pouwer, Kees Morgentin, Remy Nelson, Adam Müller, Gerhard Piechot, Alexander Tzalis, Dimitrios |
| ppnlink |
ELV011759550 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/j.drudis.2015.09.009 |
| up_date |
2024-07-06T19:59:39.287Z |
| _version_ |
1803861076778942464 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV023891211</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623171943.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2015 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.drudis.2015.09.009</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2015019000019.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV023891211</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1359-6446(15)00349-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">540</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">630</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">22</subfield><subfield code="2">ssgn</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">46.00</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Karawajczyk, Anna</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Expansion of chemical space for collaborative lead generation and drug discovery: the European Lead Factory Perspective</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2015</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">7</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">• High-quality compound collections are a main determinant of drug discovery success. • Generation of relevant collections is a significant challenge for any organization. • The European Lead Factory employs a consortium approach to address this challenge. • This has produced novel, diverse and complex compounds with reduced lipophilicity.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Giordanetto, Fabrizio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Benningshof, Jorg</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hamza, Daniel</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalliokoski, Tuomo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Pouwer, Kees</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Morgentin, Remy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nelson, Adam</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Müller, Gerhard</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Piechot, Alexander</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tzalis, Dimitrios</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="t">Triazolopyridazine LRRK2 kinase inhibitors</subfield><subfield code="d">2013</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV011759550</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:20</subfield><subfield code="g">year:2015</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:1310-1316</subfield><subfield code="g">extent:7</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.drudis.2015.09.009</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">46.00</subfield><subfield code="j">Tiermedizin: Allgemeines</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">20</subfield><subfield code="j">2015</subfield><subfield code="e">11</subfield><subfield code="h">1310-1316</subfield><subfield code="g">7</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.401374 |